Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTPa-IPV/Hib primary vaccination schedule study in healthy Chinese infants
2011-005868-25Phase 3
- Sponsor
- GSK
- Start
- Jun 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of acthib + dpt-ipv, diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + haemophilus influenzae type b conjugate vaccine and trivalent inactivated polio vaccine in diphtheria, Tetanus, pertussis and 2 more (2 arms), sponsored by GSK. Primary endpoint: Immunogenicity to study vaccine antigens.
02
Drugs
acthib + dpt-ipvdiphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + haemophilus influenzae type b conjugate vaccinetrivalent inactivated polio vaccine
03
Conditions
diphtheriaTetanuspertussispoliomyelitisHaemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on 2011-005868-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005868-25.